前列腺影像报告和数据系统指导委员会:PI-RADS v2 现状更新与未来方向
本文为 PI-RADS 指导委员会的共识专家意见,评估了 PI-RADS v2 用于多参数 MRI 检测前列腺癌的准确性、优势与不足。研究显示 PI-RADS v2 在研究和临床实践中较系统性经直肠超声引导活检保持更高准确性,能检出多数可能造成患者伤害的肿瘤,但会漏检部分癌症;其检测性能取决于临床显著疾病的定义与患病率,并需高质量诊断流程及放射科与泌尿科多学科协作。
要点
- PI-RADS v2 在研究和临床实践中较系统性经直肠超声引导活检对前列腺癌诊断保持更高准确性。
- PI-RADS v2 会漏检部分癌症,但能检出多数可能造成患者伤害、不应被漏诊的肿瘤。
- 检测性能取决于临床显著疾病的定义与患病率,良好表现需高质量诊断流程及放射科与泌尿科多学科协作。
核心结论
- 研究显示 PI-RADS v2 在研究和临床实践中的检测性能得到提升,对前列腺癌诊断较系统性经直肠超声引导活检保持更高准确性。
研究设计与样本
- 本文为 PI-RADS 指导委员会的共识专家意见,评估了临床研究、系统评价和专业指南中关于多参数 MRI 检测前列腺癌的证据。
- 证据选择基于高质量、前瞻性、经组织学验证的数据,且尽量减少患者选择偏倚和验证偏倚。
诊断标准与关键数值
- PI-RADS v2 的检测性能取决于临床显著疾病的定义和患病率。
- 在诊断流程质量得到保证、经充分培训的放射科医生与泌尿科医生在多学科团队内联合工作并实施活检的条件下,实践中可获得良好性能。
临床应用与阅片要点
- 多参数 MRI 及使用 PI-RADS 的 MRI 引导活检可提高可能造成伤害的前列腺癌检出,同时减少对未经治疗也不会造成伤害的疾病的检出。
- 成功的关键在于放射科医生和泌尿科医生在多学科团队中协作,确保高质量的影像、报告和活检。
局限性
- PI-RADS v2 不能检出所有癌症。
- 检测性能取决于临床显著疾病的定义和患病率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
CONTEXT: The Prostate Imaging-Reporting and Data System (PI-RADS) v2 analysis system for multiparametric magnetic resonance imaging (mpMRI) detection of prostate cancer (PCa) is based on PI-RADS v1, accumulated scientific evidence, and expert consensus opinion.
OBJECTIVE: To summarize the accuracy, strengths and weaknesses of PI-RADS v2, discuss pathway implications of its use and outline opportunities for improvements and future developments.
EVIDENCE ACQUISITION: For this consensus expert opinion from the PI-RADS steering committee, clinical studies, systematic reviews, and professional guidelines for mpMRI PCa detection were evaluated. We focused on the performance characteristics of PI-RADS v2, comparing data to systems based on clinicoradiologic Likert scales and non-PI-RADS v2 imaging only. Evidence selections were based on high-quality, prospective, histologically verified data, with minimal patient selection and verifications biases.
EVIDENCE SYNTHESIS: It has been shown that the test performance of PI-RADS v2 in research and clinical practice retains higher accuracy over systematic transrectal ultrasound (TRUS) biopsies for PCa diagnosis. PI-RADS v2 fails to detect all cancers but does detect the majority of tumors capable of causing patient harm, which should not be missed. Test performance depends on the definition and prevalence of clinically significant disease. Good performance can be attained in practice when the quality of the diagnostic process can be assured, together with joint working of robustly trained radiologists and urologists, conducting biopsy procedures within multidisciplinary teams.
CONCLUSIONS: It has been shown that the test performance of PI-RADS v2 in research and clinical practice is improved, retaining higher accuracy over systematic TRUS biopsies for PCa diagnosis.
PATIENT SUMMARY: Multiparametric magnetic resonance imaging (MRI) and MRI-directed biopsies using the Prostate Imaging-Reporting and Data System improves the detection of prostate cancers likely to cause harm, and at the same time decreases the detection of disease that does not lead to harms if left untreated. The keys to success are high-quality imaging, reporting, and biopsies by radiologists and urologists working together in multidisciplinary teams.
引用
- Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. Eur Urol. 2018. PMID: 29908876. doi:10.1016/j.eururo.2018.05.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。